• LAST PRICE
    0.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.0000
  • Day Range
    Low 0.0000
    High 0.0000
  • 52 Week Range
    Low 0.0000
    High 1.0400
  • Volume
    44
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDMKPQ
DMK Pharmaceuticals Corp
10.0
0.0x
---
United StatesPCYN
Procyon Corp
1.6M
-5.2x
---
United StatesEVOK
Evoke Pharma Inc
7.4M
-0.3x
---
United StatesBSPM
Biostar Pharmaceuticals Inc
260.0
0.0x
---
United StatesAXMP
Aaron Sparks Industries Inc
410.0
0.0x
---
United StatesPLSH
Panacea Life Sciences Holdings Inc
2.1M
-0.2x
---
As of 2024-11-13

Company Information

DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.

Contact Information

Headquarters
11682 El Camino Real, Suite 300SAN DIEGO, CA, United States 92130
Phone
858-997-2400
Fax
302-636-5454

Executives

Chief Restructuring Officer
Seth Cohen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.00
Revenue (TTM)
$3.6M
Shares Outstanding
10.1M
DMK Pharmaceuticals Corp does not pay a dividend.
Beta
1.38
EPS
$-8.69
Book Value
$-0.30
P/E Ratio
0.0x
Price/Sales (TTM)
0.0
Price/Cash Flow (TTM)
---
Operating Margin
-685.86%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.